You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
尖峯集團(600668.SH):鹽酸莫西沙星滴眼液獲得藥品註冊證書
格隆匯 10-24 16:00

格隆匯10月24日丨尖峯集團(600668.SH)公佈,公司的控股子公司浙江尖峯藥業有限公司(稱“尖峯藥業”)收到國家藥品監督管理局核准簽發的鹽酸莫西沙星滴眼液《藥品註冊證書》(證書編號:2023S01585、2023S01586),鹽酸莫西沙星,是由拜耳公司於1999年開發的第四代超廣譜氟喹諾酮類抗菌藥,其滴眼液是由諾華製藥開發的一種治療由敏感微生物引起的細菌性結膜炎的眼用製劑。

本次尖峯藥業獲得鹽酸莫西沙星滴眼液《藥品註冊證書》,標誌着尖峯藥業具有進行該藥品生產,銷售的資格,將進一步豐富尖峯藥業的產品種類,有助於提升公司醫藥業務的競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account